Controls nausea and vomiting associated with certain types of anesthesia and surgery. ANDA 216446, held by Annora Pharma. Promethazine Hydrochloride.
As of Nov 16, 2026, ANDA 216446 (Promethazine Hydrochloride), held by Annora Pharma, was first approved by FDA on Nov 2, 2022, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Promethazine hydrochloride suppositories are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 2, 2022 | Original application | Approved | None posted |
| Promethazine Hydrochloride12.5MG · suppository;rectal | Promethazine Hydrochloride | Rx |
| Promethazine Hydrochloride25MG · suppository;rectal | Promethazine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters